Back to search results
NCT06300502

Assessing the Efficacy of Repeat, Monthly Treatments of Deoxycholate for NF1 Associated Cutaneous Neurofibromas (cNFs)

Enrolling by Invitation
PHASE1Ages 18–85Interventional
Massachusetts General Hospital
~15 participants
Updated 2026-04-22 on ClinicalTrials.gov
What's tested:Kybella

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
Measured over 3 months after treatment

Conditions

Neurofibromas, Cutaneous
Neurofibromatosis 1

Explore related trials

Neurofibromatosis Type 1Skin NeurofibromaNF1 Gene

Where it's being run

1 sites across 1 states
Massachusetts1

Study leadership

  • Richard R Anderson, MD · PRINCIPAL_INVESTIGATOR · Massachusetts General Hospital

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Family history of NF1,
Six or more light brown ("cafe-au-lait") spots on the skin,
Presence of two or more neurofibromas of any type, or one or more plexiform neurofibromas,
Freckling under the arms or in the groin area,
Two or more pigmented, benign bumps on the eye's iris (Lisch nodules),
A distinctive bony lesion: dysplasia (abnormal growth) of the sphenoid bone behind the eye, or dysplasia of long bones, often in the lower leg,
Tumor on the optic nerve that may interfere with vision. 3. Participant is seeking treatment for cNF. 4. Participant has ≥ 6 paired cNF that are visible and measure 2 mm or more in size. The target treatment area must be amenable to both deoxycholate injections and surveillance with digital and 3D photography. Preferred locations are trunk (back or chest), arms and legs. 5. Participant is able and willing to comply with all visit, treatment and evaluation schedules and requirements. 6. Participant is able to understand and provide written informed consent. 7. Participant has no known allergy to deoxycholate. 8. Participant has no concurrent injury or wound in the target area.

What this trial measures

  • Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]3 months after treatment

    Treatment will be considered tolerable if \<40% of participants treated have a \>grade 2 CTCAE v5 adverse event (AE).